Reuters logo
BRIEF-Opdivo demonstrates superior 3-yr survival benefit for patients with previously treated advanced RCC
November 6, 2017 / 12:26 PM / 12 days ago

BRIEF-Opdivo demonstrates superior 3-yr survival benefit for patients with previously treated advanced RCC

Nov 6 (Reuters) - Bristol-Myers Squibb Co

* Opdivo (nivolumab) demonstrates superior three-year survival benefit for patients with previously treated advanced renal cell carcinoma (RCC)

* ‍Median OS, primary endpoint in this study, for Opdivo was 25.8 months compared to 19.7 months with Everolimus

* Bristol-Myers Squibb says ‍Opdivo (nivolumab) demonstrates superior 3-year survival benefit for patients with previously treated advanced RCC ​

* Bristol-Myers Squibb - ‍No new safety signals were identified in 3-year OS update, data showed safety profile consistent with 2-year results Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below